Krystal Biotech, Inc. KRYS Legal contingency and settlement
Legal contingency and settlement at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GainLossRelatedToLitigationSettlement.
The official record: Krystal Biotech, Inc.’s 10-K, filed February 17, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s legal contingency and settlement.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s legal contingency and settlement?
- Krystal Biotech, Inc. (KRYS) reported legal contingency and settlement of $0 in Q4 2025.
- How has Krystal Biotech, Inc.'s legal contingency and settlement changed year-over-year?
- Krystal Biotech, Inc.'s legal contingency and settlement increased by 100.0% year-over-year, from -$9.38M to $0.
- What is the long-term trend for Krystal Biotech, Inc.'s legal contingency and settlement?
- Over 2 years (2023 to 2025), Krystal Biotech, Inc.'s legal contingency and settlement has grown at a -100.0% compound annual growth rate (CAGR), from -$12.5M to $0.
- What does legal contingency and settlement mean?
- Costs or gains resulting from legal disputes and settlements.
- How do you interpret legal contingency and settlement?
- An increase in losses signals potential legal risk or operational liability, while gains may represent one-time recoveries.
- How does legal contingency and settlement compare across companies?
- Highly variable across companies; often treated as an extraordinary or non-recurring item.